Key Points
Soleus increased its Celcuity stake by 629,398 shares.
The firm held over 1.8 million shares at the end of the quarter.
Celcuity now accounts for 6.7% of fund AUM
- 10 stocks we like better than Celcuity ›
On Feb. 12, Soleus Capital Management, L.P. disclosed a buy of 629,398 shares of Celcuity (NASDAQ:CELC)in a Securities and Exchange Commission (SEC) filing
- Soleus increased its Celcuity stake by 629,398 shares.
- After the trade, it held more than 1.8 million shares valued at $180.36 million.
- Celcuity now accounts for 6.7% of the fund’s AUM.
What else to know
- Top five fund holdings at quarter end:
- NYSEMKT: XBI: $354.6 million (13% of AUM)
- NASDAQ:KRYS: $232.0 million (8.6% of AUM)
- NASDAQ: CELC: $180.4 million (6.7% of AUM)
- NASDAQ:NVCR: $110.3 million (4.1% of AUM)
- NASDAQ:PRAX: $107.0 million (3.9% of AUM)
Company overview
| Metric | Value |
|---|---|
| Price (as of market close February 11, 2026) | $104.23 |
| Market capitalization | $4.85 billion |
| Net income (TTM) | ($162.7 million) |
Company snapshot
Celcuity is a clinical-stage biotechnology firm focused on innovative cancer diagnostics and targeted therapies, leveraging its CELsignia platform to identify and address specific cellular drivers of cancer. The company’s strategy centers on advancing Gedatolisib and companion diagnostics to address unmet needs in breast and ovarian cancer treatment.
- Celcuity develops molecularly targeted therapies and diagnostic platforms for cancer treatment, including its lead drug candidate Gedatolisib and the CELsignia MP test for breast and ovarian cancers.
- The company operates a clinical-stage biotechnology model, generating value through the development and potential commercialization of proprietary therapies and diagnostic tests, with future revenue expected from licensing, partnerships, and product sales.
- Celcuity primarily targets oncologists, healthcare providers, and biopharmaceutical partners serving patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.
What this transaction means for investors
Soleus Capital Management sent a bullish signal to the market with its significant purchase of Celcuity shares. Owning 1.2 million shares on Sept. 30, the firm boosted its position to over 1.8 million shares by the end of the year.
Previously, its holding represented the firm’s ninth-largest position. As of Dec. 31, it became the third-largest holding among its 95 positions revealed in its 13F filing. Its shares had a value of $180.4 million, with total holdings worth $2.7 billion.
Celcuity shares have had a remarkable run over the last year. The price increased a remarkable 745% over the last year through Feb. 12. By comparison, the S&P 500 index returned 14.4%, and the NASDAQ Composite had a total return of 15.7%.
Currently, Celcuity doesn’t produce any revenue. Hence, investors should note the stock’s inherent risk, with the stock trading on the promise of drug approvals and potential revenue and profitability.
Should you buy stock in Celcuity right now?
Before you buy stock in Celcuity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Celcuity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $429,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,165,045!*
Now, it’s worth noting Stock Advisor’s total average return is 913% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of February 13, 2026.
Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Krystal Biotech and NovoCure. The Motley Fool recommends DexCom and TG Therapeutics and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
